{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:34:00Z","timestamp":1787924040364,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 GM136906-03S1"],"award-info":[{"award-number":["R01 GM136906-03S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.biopha.2024.117718","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T21:10:28Z","timestamp":1733346628000},"page":"117718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Combining supervised and unsupervised analyses to quantify behavioral phenotypes and validate therapeutic efficacy in a triple transgenic mouse model of Alzheimer's disease"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9812-0871","authenticated-orcid":false,"given":"Thais","family":"Del Rosario Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra R.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayali V.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill A.","family":"Kreiling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8236-6422","authenticated-orcid":false,"given":"Robbert","family":"Creton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117718_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.biopha.2024.117718_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002369","article-title":"Alzheimer's disease: the challenge of the second century","volume":"3","author":"Holtzman","year":"2011","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.biopha.2024.117718_bib3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3233\/JAD-230526","article-title":"Reduced Prevalence of Dementia in Patients Prescribed Tacrolimus, Sirolimus, or Cyclosporine","volume":"95","author":"Silva","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2024.117718_bib4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/JAD-150065","article-title":"Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors","volume":"47","author":"Taglialatela","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2024.117718_bib5","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1038\/s41598-022-10133-y","article-title":"Novel use of FDA-approved drugs identified by cluster analysis of behavioral profiles","volume":"12","author":"Tucker Edmister","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117718_bib6","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1038\/s41598-023-30303-w","article-title":"Zebrafish Larvae Position Tracker (Z-LaP Tracker): a high-throughput deep-learning behavioral approach for the identification of calcineurin pathway-modulating drugs using zebrafish larvae","volume":"13","author":"Gore","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117718_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/cpns.81","article-title":"Overview of Transgenic Mouse Models for Alzheimer's Disease","volume":"89","author":"Myers","year":"2019","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.biopha.2024.117718_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2024.117718_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/JAD-201014","article-title":"Sexual Dimorphism in the 3xTg-AD Mouse Model and Its Impact on Pre-Clinical Research","volume":"80","author":"Dennison","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2024.117718_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-024-00712-0","article-title":"Updates on mouse models of Alzheimer's disease","volume":"19","author":"Zhong","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.biopha.2024.117718_bib11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.neubiorev.2020.02.012","article-title":"Behavioural and psychological symptoms of dementia in mouse models of Alzheimer's disease-related pathology","volume":"112","author":"Kosel","year":"2020","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.biopha.2024.117718_bib12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbr.2012.07.004","article-title":"Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD)","volume":"234","author":"Filali","year":"2012","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.biopha.2024.117718_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13024-017-0231-7","article-title":"Practical considerations for choosing a mouse model of Alzheimer's disease","volume":"12","author":"Jankowsky","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.biopha.2024.117718_bib14","unstructured":"Bryan, K.J., Lee, H.-g, Perry, G., Smith, M.A., and Casadesus, G. (2009). Transgenic Mouse Models of Alzheimer\u2019s Disease: Behavioral Testing and Considerations. 2nd ed. CRC Press\/Taylor & Francis, Boca Raton (FL)."},{"key":"10.1016\/j.biopha.2024.117718_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.713726","article-title":"Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study","volume":"13","author":"Oblak","year":"2021","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.biopha.2024.117718_bib16","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1038\/s41598-023-35322-1","article-title":"An 8-cage imaging system for automated analyses of mouse behavior","volume":"13","author":"Del Rosario Hern\u00e1ndez","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117718_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101365","article-title":"Modeling Functional Limitations, Gait Impairments, and Muscle Pathology in Alzheimer's Disease: Studies in the 3xTg-AD Mice","volume":"9","author":"Castillo-Mariqueo","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2024.117718_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1590\/S0101-60832012000500003","article-title":"Altera\u00e7\u00f5es motoras e funcionais em diferentes est\u00e1gios da doen\u00e7a de Alzheimer.","volume":"39","author":"Zidan","year":"2012","journal-title":"Rev. Psiquiatr. Clin."},{"key":"10.1016\/j.biopha.2024.117718_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.112158","article-title":"Progressive age-dependent motor impairment in human tau P301S overexpressing mice","volume":"376","author":"Koivisto","year":"2019","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.biopha.2024.117718_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105404","article-title":"Transgenic Mouse Models of Alzheimer's Disease: An Integrative Analysis","volume":"23","author":"Sanchez-Varo","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117718_bib21","article-title":"Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview","volume":"14","author":"de Bem","year":"2020","journal-title":"Front Neurosci."},{"key":"10.1016\/j.biopha.2024.117718_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.912995","article-title":"Mouse Models of Alzheimer's Disease","volume":"15","author":"Yokoyama","year":"2022","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.biopha.2024.117718_bib23","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3233\/JAD-2012-120904","article-title":"Investigation of nebivolol as a novel therapeutic agent for the treatment of Alzheimer's disease","volume":"33","author":"Wang","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2024.117718_bib24","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/j.1476-5381.2009.00610.x","article-title":"The selective beta1-adrenoceptor antagonist nebivolol is a potential oestrogen receptor agonist with neuroprotective abilities","volume":"159","author":"Manthey","year":"2010","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2024.117718_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/alz.12871","article-title":"Hypertension and hyperhomocysteinemia as modifiable risk factors for Alzheimer's disease and dementia: New evidence, potential therapeutic strategies, and biomarkers","volume":"19","author":"Carey","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopha.2024.117718_bib26","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2019.12.033","article-title":"The Alzheimer's Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease: JACC Focus Seminar","volume":"75","author":"Stakos","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2024.117718_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14737175.2020.1708195","article-title":"Antihypertensive agents in Alzheimer's disease: beyond vascular protection","volume":"20","author":"Lebouvier","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.biopha.2024.117718_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13041-023-01051-9","article-title":"Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD","volume":"16","author":"Lee","year":"2023","journal-title":"Mol. Brain"},{"key":"10.1016\/j.biopha.2024.117718_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108171","article-title":"Enhancing autophagy in Alzheimer's disease through drug repositioning","volume":"237","author":"Eshraghi","year":"2022","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2024.117718_bib30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1213\/ANE.0000000000004183","article-title":"Chronic Calcineurin Inhibition via Cyclosporine A Impairs Visuospatial Learning After Isoflurane Anesthesia","volume":"129","author":"Speigel","year":"2019","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.biopha.2024.117718_bib31","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1089\/thy.2013.0137","article-title":"In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.biopha.2024.117718_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.220","article-title":"Evaluating Gait and Locomotion in Rodents with the CatWalk","volume":"1","author":"Garrick","year":"2021","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.biopha.2024.117718_bib33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/neu.2006.23.537","article-title":"CatWalk-assisted gait analysis in the assessment of spinal cord injury","volume":"23","author":"Hamers","year":"2006","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.biopha.2024.117718_bib34","article-title":"Keypoint-MoSeq: parsing behavior by linking point tracking to pose dynamics","author":"Weinreb","year":"2023","journal-title":"bioRxiv"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224016044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224016044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:08:09Z","timestamp":1787922489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224016044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"alternative-id":["S0753332224016044"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117718","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.07.597924","asserted-by":"object"}]},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining supervised and unsupervised analyses to quantify behavioral phenotypes and validate therapeutic efficacy in a triple transgenic mouse model of Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117718"}}